SEC Form SC 13G/A filed

2/11/21 2:40:13 PM ET

Major Pharmaceuticals

Health Care

Get the next $FLXN alert in real time by email

SC 13G/A 1 flxn221.txt SCHEDULE 13G Amendment No. 1 Name of Issuer: Flexion Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 33938J106 Item 1: Reporting Person: Wasatch Advisors, Inc. 87-0319391 Item 2: Check Box If Member of Group: Not Applicable Item 3: SEC Use Item 4: Place of Organization: Utah Items 5-8: Number of Shares Owned With: Item 5: Sole Voting Power: 4,109,494 Item 6: Shared Voting Power: 0 Item 7: Sole Dispositive Power: 4,109,494 Item 8: Shared Dispositive Power: 0 Item 9: Aggregate Amount Owned: 4,109,494 Item 10: Check Box If Aggregate Amount Excludes Certain Shares: N/A Item 11: Percent of Class Owned: 8.3% Item 12: Type of Reporting Person: IA Item 1(a): Name of Issuer: Flexion Therapeutics Inc. Item l(b): Address of Issuer: 10 Mall Road, Ste 301, Burlington, MA 01803 Item 2(a): Name of Person Filing: Wasatch Advisors, Inc. Item 2(b): Address: 505 Wakara Way, Salt Lake City, UT 84108 Item 2(c): Citizenship: Not Applicable Item 2(d): Title of Class of Securities: Common Stock Item 2(e): CUSIP Number: 33938J106 Item 3(e): Investment Adviser registered under section 203 of the Investment Advisers Act of 1940 Item 4(a): Amount Owned: 4,109,494 Item 4(b): Percent of Class Owned: 8.3% Item 4(c)(i): Sole Voting Power: 4,109,494 Item 4(c)(ii): Shared Voting Power: 0 Item 4(c)(iii): Sole Dispositive Power: 4,109,494 Item 4(c)(iv): Shared Dispositive Power: 0 Item 5: Check Box If Ownership Is 5% or Less of Class: [ ] Item 6. Ownership of More Than 5% on Behalf of Another Person: N/A Item 7: Identification of Subsidiary: Not Applicable Item 8: Identification of Members of Group: Not Applicable Item 9: Notice of Dissolution of Group: Not Applicable Item 10: Certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct as of December 31, 2020. Date: 02/11/21 Signature: /s/JB Taylor Name/Title: JB Taylor/CEO

Get the next $FLXN alert in real time by email

Date	Price Target	Rating	Analyst
11/19/2021		Outperform → Market Perform	Northland Capital Markets
10/19/2021	$25.00 → $10.00	Buy → Neutral	HC Wainwright & Co.
10/12/2021	$20.00 → $12.00	Outperform → Market Perform	BMO Capital
10/12/2021		Strong Buy → Market Perform	Raymond James
10/12/2021	$14.00 → $10.00	Outperform → Neutral	Credit Suisse
8/6/2021	$8.00 → $6.00	Neutral	Goldman Sachs
8/5/2021	$20.00 → $18.00	Buy	Needham

SEC Form SC 13G/A filed

Chat with this insight

Recent Analyst Ratings for
$FLXN

$FLXN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Flexion Therapeutics downgraded by Northland Capital Markets

Flexion Therapeutics downgraded by HC Wainwright & Co. with a new price target

Flexion Therapeutics downgraded by BMO Capital with a new price target

SEC Form SC 13G/A filed

Chat with this insight

Recent Analyst Ratings for $FLXN

$FLXN Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Flexion Therapeutics downgraded by Northland Capital Markets

Flexion Therapeutics downgraded by HC Wainwright & Co. with a new price target

Flexion Therapeutics downgraded by BMO Capital with a new price target

Recent Analyst Ratings for
$FLXN

$FLXN
Analyst Ratings